EVOEvotec SE

Nasdaq evotec.com


$ 4.74 $ 0.12 (2.61 %)    

Tuesday, 25-Jun-2024 15:49:59 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 4.72
$ 4.72
$ 0.00 x 0
$ 0.00 x 0
$ 4.72 - $ 4.74
$ 3.94 - $ 13.49
59,687
na
835.22M
$ 0.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 german-drug-developer-evotec-seeks-adviser-input-as-takeover-concerns-mount

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.

 evotec-consults-defense-advisers-following-share-selloff-amid-takeover-concerns-several-buyout-firms-evaluating-company-and-drug-pipeline-incoming-ceo-christian-wojczewski-to-assess-situation-before-strategic-decisions

- Bloomberg

 evotec-joins-forces-with-inserm-and-lille-university-hospital-to-identify-key-mechanisms-in-obesity-and-metabolic-diseases

Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity ...

 hc-wainwright--co-reiterates-buy-on-evotec-maintains-11-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Evotec (NASDAQ:EVO) with a Buy and maintains $11 price target.

 evotec-q1-eps-007-beats-010-estimate-sales-22669m-beat-22257m-estimate

Evotec (NASDAQ:EVO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 35 p...

Core News & Articles

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies...

 bayer-and-evotec-collaborate-to-advance-precision-cardiology-financial-terms-undisclosed

Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic co...

 hc-wainwright--co-maintains-buy-on-evotec-lowers-price-target-to-11

HC Wainwright & Co. analyst Douglas Tsao maintains Evotec (NASDAQ:EVO) with a Buy and lowers the price target from $14 t...

 life-science-focused-evotec-shares-plunge-to-6-year-lows-on-gloomy-annual-forecast

Evotec undergoes a strategic shift for sustainable growth in 2024. Priority reset to optimize operations; expect double-digit r...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION